GlassScriptPhysician profile
Dorothy Miller
NPI 1922075126
$10,084.40
in general payments reported to CMS, 2019-2025
52 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,053 · 2020: $1,083 · 2021: $1,553 · 2022: $1,798 · 2023: $1,458 · 2024: $1,076 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.93 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,409.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,045.86 | 2020-2025 | |
| Glaxosmithkline, LLC. | $957.26 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $921.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $796.25 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $549.23 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.55 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Pfizer INC. | $348.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $346.80 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Janssen Pharmaceuticals, INC | $344.93 | 2019-2022 | |
| Allergan, INC. | $300.76 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $214.54 | 2021-2024 | Ajovy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $181.84 | 2019-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.90 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $158.29 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.